Kalbe Farma strategies in 2H15.
In 2H15, Kalbe Farma (KLBF) will focus on high-margin products such as cancer medicines and ready-to-drink milk to maintain its financial performance in 2015. The company has commenced operation of an oncology drug plant in 2H14, but the contribution to total revenue is still small. The company is building a biosimilar factory in Cikarang with US$25m-30m investment. The company hopes this biosimilar factory can contribute 10% to total revenue in the next 7-10 years. The biosimilar factory will be completed sometime in 2018-19 and requires a further 1-3 years to develop the products. The company is looking for JV partner in Thailand and Vietnam to increase its export sales. In addition, the liquid milk plant in Sukabumi is still being completed.